Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,859 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Birmingham, AlabamaAges 12 years+ - NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07787208RecruitingPhase 1
Experimental drug for advanced solid tumors
This trial tests an investigational drug called ONO-7429 for people with advanced or recurrent solid tumors that have not responded to standard treatments. The goal is to see if the drug can help control the cancer.
Kashiwa, ChibaAges 18 years+ - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT05272709RecruitingPhase 1/Phase 2
New pill TT-702 for advanced solid tumors
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
LondonAges 16 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06526819RecruitingPhase 1/Phase 2
New drug SMP-3124LP for advanced solid tumors
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Los Angeles, CaliforniaAges 18 years+ - NCT06880549RecruitingPhase 1
mRNA cancer vaccine study for advanced solid tumors
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT06985368RecruitingPhase 1
Testing SIBP-A18 for advanced solid tumors
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Beijing, Beijing MunicipalityAges 18–75 - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+ - NCT06782334RecruitingPhase 1/Phase 2
AMT-116 for advanced solid tumors
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06378593RecruitingPhase 1/Phase 2
Study of drug 3HP-2827 for tumors with FGFR2 changes
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233292RecruitingPhase 1/Phase 2
Study of ZG005 for advanced solid tumors
This trial tests a new drug called ZG005 in people with advanced solid tumors that have not spread to the brain. It aims to see if the drug is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18–70 - NCT06117566RecruitingPhase 1/Phase 2
WX390 plus Toripalimab for advanced solid tumors
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Changchun, JilinAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,859 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.